35 results about "Genetically modified microorganisms" patented technology

This disclosure relates to compositions and methods using genetically modified bacteria that express superoxide dismutase (SOD) and catalase enzymes to reduce oxidative stress in the skin, and can be used for various skin conditions. In some embodiments of this disclosure, the genetically modified bacteria are Gram-positive bacteria, for example, of the genus Corynebacterium.

The present disclosure relates to a genetically modified microorganism satisfying some of predetermined conditions. The predetermined conditions include: (I) succinate dehydrogenase activity or fumarate reductase activity being reduced or inactivated relative to a wild-type microorganism; (II) lactate dehydrogenase activity being reduced or inactivated relative to the wild-type microorganism; (III) the genetically modified microorganism having modified phosphoenolpyruvate carboxylase activity showing resistance to feedback inhibition by aspartic acid in wild-type phosphoenolpyruvate carboxylase activity, or exogenous phosphoenolpyruvate carboxylase activity having higher resistance to feedback inhibition by aspartic acid than that of the wild-type phosphoenolpyruvate carboxylase activity shown by the wild-type microorganism; and (IV) pyruvate:quinone oxidoreductase being reduced or inactivated relative to the wild-type microorganism.

Disclosed herein are genetically engineered Kluyveromyces sp. cells capable of producing D-allulose. The genetically engineered Kluyveromyces sp. cells comprise an exogenous polynucleotide sequence encoding an allulose-6-phosphate 3-epimerase enzyme at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or100% identical to at least one of SEQ ID NOs:249-256, 258, and 259; and an exogenous polynucleotide sequence encoding an allulose-6-phosphate phosphatase enzyme at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100% identical to at least one of SEQ ID NOs:87, 89, 190, 123, 105, 107, 115, 83, 95, 113, 117, 119, 121, 127, 131, 137, 145, 169, 173, 179, and 183.

Disclosed herein are genetically engineered Kluyveromyces marxianus cells capable of producing D-allulose with increased talitol formation. The engineered cell may comprise a genetic modification resulting in overexpression of a native talitol dehydrogenase enzyme; an exogenous polynucleotide sequence encoding an allulose-6-phosphate 3-epimerase enzyme at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100% identical to at least one of SEQ ID NOs:249-256, 258, and 259; and an exogenous polynucleotide sequence encoding an allulose-6-phosphate phosphatase enzyme at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100% identical to at least one of SEQ ID NOs:87, 89, 190, 123, 105, 107, 115, 83, 95, 113, 117, 119, 121, 127, 131, 137, 145, 169, 173, 179, and 183.

The present description relates to a transgenic microorganism capable of converting vegetable oils into olefins. The present description also discloses a process for obtaining such hydrocarbons from triglycerides or free fatty acids of plant origin, which is carried out by the microorganism disclosed in the present description.

Methods and kits are provided for producing Griffithsin. The methods include providing a genetically modified microorganism comprising a gene encoding Griffithsin protein operably linked to an inducible promotor and growing the genetically modified microorganism under conditions that induce the promotor and cause expression of griffithisin. The Griffithsin is purified by releasing Griffithsin from the microorganism by cellular disruption, performing a precipitation step to remove contaminating protein and nucleic acids, and performing an anion exchange chromatography step.

Methods for producing organosulfur compounds from a prokaryotic cell comprising enzymes involved in the production of cysteamine, hypotaurine, and taurine. Said prokaryote may comprise a vanin selected from vanin-1 (vnn-1), vanin-2 (vnn-2), or vanin- 3 (vnn-3), a cysteamine dioxygenase (ado), and / or a flavin-containing monooxygenase 1 (fmo1). Methods include the expression of organosulfur compounds in Corynebacterium glutamicum with incubation conditions to promote compound production.

The purpose of the present disclosure is to provide: a method for producing β-carotene and a β-carotene derivative; and a genetically modified microorganism. The present disclosure provides: a method for producing β-carotene and / or a β-carotene derivative using a genetically modified microorganism that belongs to the genus Lipomyces; and a genetically modified microorganism that belongs to the genus Lipomyces, and that has a β-carotene biosynthesis pathway and produces β-carotene and / or a β-carotene derivative through fermentation.

The present invention relates to an enzyme cocktail, a method for the deconstruction of lignocellulosic biomass using said cocktail, and a genetically modified microorganism for producing heterologous enzyme aimed at making biomass fermentable into biorenewable products such as biofuels, organic acids, and hydrocarbon.

A genetically modified microorganism that can produce 3-hydroxyadipic acid and / or α-hydromuconic acid with a high yield; and a method of producing 3-hydroxyadipic acid and / or α-hydromuconic acid using the genetically modified microorganism, are disclosed. The genetically modified microorganism has an ability to produce 3-hydroxyadipic acid and / or α-hydromuconic acid, and has an enhanced enzymatic activity to catalyze a reaction to reduce 3-oxoadipyl-CoA to 3-hydroxyadipyl-CoA, wherein, in the genetically modified microorganism, a dicarboxylic acid excretion carrier function is deleted or decreased.

Among the various aspects of the present disclosure is the provision of a biological and biochemical production of piperazic acid derived from the newly discovered production pathway for L-piperazic acid. One aspect of the present disclosure includes a transgenic microorganism (e.g., bacteria) engineered to accumulate piperazic acid and derivatives thereof, including a piperazic acid (Piz)-containing product. Another aspect of the present disclosure includes biochemical and biological methods for producing piperazic acid and derivatives thereof, including a piperazic acid (Piz)-containing product. Another aspect of the present disclosure includes compositions and methods of using isotopically labeled piperazic acid and derivatives thereof, including a piperazic acid (Piz)-containing product.

The invention belongs to the food industry, relates to a novel method for producing casein compositions by culturing transgenic microorganisms in the presence of whey, and limits the environmental impact.

The present invention provides a method for producing liquid methionine or methionine, and particularly provides a method for producing liquid methionine or methionine by condensation reaction of 3-hydroxypropionaldehyde and formyl-CoA derived from a C1 substrate. The present invention also provides a genetically engineered microorganism for the production of liquid methionine or methionine.

A method for producing isoprene glycol, including: enzymatically generating 3-hydroxy-3-methylbutyryl-CoA (HMB-CoA) from acetyl-CoA (Ac-CoA); enzymatically generating 3-methyl-3-hydroxybutyrylaldehyde (3-HMBA) from HMB-CoA; and enzymatically converting 3-HMBA to isoprene glycol (ISPG). Wherein the enzymatically generating 3-HMBA from HMB-CoA includes: enzymatically reducing HMB-CoA to produce 3-HMB; or enzymatically hydrolyzing HMB-CoA to 3-hydroxy-3-methylbutyric acid (HMB) and then enzymatically reducing HMB to 3-HMBA. Also provided herein are an enzyme composition, a nucleic acid composition, and a transgenic microorganism for producing isoprene glycol.

This disclosure relates to genetically modified microorganisms for improving plant phenotypes, such as nitrogen use efficiency in non-leguminous plants. It includes novel strains of microorganisms, microbial aggregates, and agricultural compositions comprising them. Furthermore, this disclosure teaches methods for utilizing the described microorganisms, the microbial aggregates, and the agricultural compositions comprising them in methods for conferring beneficial properties to target plant species. In a particular aspect, this disclosure provides methods for enhancing desired plant traits of agronomically important species, such as nitrogen fixation, utilization, regulation, absorption, acquisition, tolerance, and / or treatment in plants.

The present invention refers to the heterologous production in microorganisms of modified versions of a predicted isoform of the surfactant protein Lv-ranaspumin-1 (Lv-Rsn-1), whose sequence was inferred from analyzes of the protein extract of the nest foam from the Northeastern Pepper Frog (Leptodactylus vastus). More specifically, it refers to two surfactant proteins that consist of modified versions of the predicted isoform of Lv-Rsn-1; to two synthetic genes each encoding one of these modified versions of the predicted isoform of Lv-Rsn-1; to two expression cassettes each containing one of the synthetic genes encoding one of the modified versions of the predicted isoform of Lv-Rsn-1; to two expression vectors each containing one of the synthetic genes encoding modified versions of the predicted isoform of Lv-Rsn-1; and to two transgenic microorganisms, a bacterium and a yeast, each transformed with one of these synthetic genes and heterologously producing one of the modified versions of the predicted isoform of Lv-Rsn-1. Lv-Rsn-1 has surfactancy, emulsification and dispersancy properties, among others, and its heterologous production allows it to be used in various applications and industrial products, without the need to extract it from the frog nest foam.

To provide a cytidine diphosphate choline glycoside and a method for producing a glycoside of a cytidine residue-containing compound.SOLUTION: Provided is a cytidine diphosphate choline glycoside represented by the following general formula (1), a salt thereof, an N-oxide thereof, or a solvate thereof. (In the formula (1), R is a sugar residue.). ) SELECTED DRAWING: None

The present disclosure provides materials and methods related to the production of peptides and polypeptides from engineered microorganisms. In particular, the present disclosure provides compositions and methods for producing a genetically modified microorganism (e.g., yeast cell) with enhanced protein expression and / or secretion.

The present disclosure provides gene constructs comprising genes coding forenzymes involved in: converting tryptophan into indole; converting indole into indoxyl; and production of tryptophan from phosphoenolpyruvate and erythrose 4-phosphate. When such gene constructs are expressed in a genetically modified microorganism of the present disclosure, they enable the significant production and accumulation of tryptophan, indole and / or indoxyl within the cells, without the need to supply tryptophan from external sources. The genetically modified microorganism of the present disclosure includes one or more overexpressed genes alongwith one or more knocked-down genes such as tryptophan operon regulator, tyrosine aminotransferase, aspartate aminotransferase, tryptophan repressor protein, pykA, pykF, and combinations thereof. The genetically modified microorganism is capable of using glucose and glycerol as a carbon source to grow and produce indigo. The present disclosure also provides methods for preparing the genetically modified microorganism as well as method of producing indigo from said microorganism.

A method of producing an organosulfur compound from a prokaryotic cell wherein said method comprises the steps of:a. providing a live prokaryotic cell capable of expressing at least one gene for the production of said organosulfur compound;b. exposing said live prokaryotic cell to a culture media with a pH of between 4 and 11 containing a carbon source and a sulfur source thereby creating an incubation mixture;c. incubating said live prokaryotic cell in said incubation mixture under aerobic or anaerobic conditions at a temperature ranging from 0° C. to 60° C. for a period of time sufficient for the expression of said at least one gene for the production of said organosulfur compound;d. recovering said organosulfur compound from the bacterial cells and / or spent media; ande. optionally, re-exposing said live prokaryotic cell to an unused media or spent media for the continuous production of said organosulfur compound of interest.

The present disclosure relates to the use of switches for the production of heterologous non-catabolic compounds in microbial host cells. In one aspect, provided herein are genetically modified microorganisms that more stably produce non-catabolic compounds when cultured continuously under aerobic conditions followed by microaerobic conditions, and methods of producing non-catabolic compounds by culturing the genetically modified microorganisms under such culture conditions. In another aspect, provided herein are genetically modified microorganisms that more stably produce non-catabolic compounds when cultured continuously in the presence of maltose followed by reduced or no maltose, and methods of producing non-catabolic compounds by culturing the genetically modified microorganisms under such culture conditions.

A genetically modified microorganism for increasing the production of a polyketide compound or a derivative thereof is provided, including any one or both of the following genetic modifications: (a) a deleted endogenous pta gene encoding a phosphate acetyltransferase, wherein an expression level of the phosphate acetyltransferase of the deleted endogenous pta gene is lower than an expression level of its wild type; and (b) an added first exogenous nucleotide sequence and second exogenous nucleotide sequence, wherein the first exogenous nucleotide sequence encodes a transaminase and the second exogenous nucleotide sequence encodes a reductase. A method for producing a polyketide compound or a derivative thereof using the aforementioned genetically modified microorganism is also provided.

The present disclosure relates to genetically modified bacteria, wherein said genetically modified bacteria is designed to express or overexpress a heme-containing protein. Said protein is optionally expressed or overexpressed in combination with one or more enzymes that catalyze the heme synthesis pathway. Said genetically modified organism allows scalable production of heme-containing protein with the advantage that the expressed protein remains in soluble form without forming inclusion bodies.

Disclosed herein are genetically engineered Kluyveromyces marxianus cells capable of producing D-allulose with reduced allitol by-product formation. The engineered cell may comprise a deletion or disruption of a native allitol dehydrogenase gene; an exogenous polynucleotide sequence encoding an allulose-6-phosphate 3-epimerase enzyme at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100% identical to at least one of SEQ ID NOs:249-256, 258, and 259; and an exogenous polynucleotide sequence encoding an allulose-6-phosphate phosphatase enzyme at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100% identical to at least one of SEQ ID NOs:87, 89, 190, 123, 105, 107, 115, 83, 95, 113, 117, 119, 121, 127, 131, 137, 145, 169, 173, 179, and 183.

The present invention relates to the food industry and to a novel method for producing a casein composition while limiting environmental impact by culturing transgenic microorganisms in the presence of whey, and to the use thereof, in particular for producing cheese substitutes.

The present invention relates to a method for producing L-methionine comprising the fermentation under aerobic conditions of a genetically modified microorganism which produces more L-methionine than the microorganism before the genetical modification in a medium comprising a primary alcohol upon increasing the activity of the glyoxylate shunt.

The present invention relates to a protein that has an amino acid sequence having 80% or more identity with the amino acid sequence represented by SEQ ID NO: 1, has at least one feature selected from the group consisting of features (1) to (5), and has activity for uptake of a lacto-N-triose II-containing oligosaccharide. (1) The amino acid residue corresponding to the 60th amino acid residue of the amino acid sequence represented by SEQ ID NO: 1 is aspartic acid. (2) The amino acid residue corresponding to the 119th amino acid residue of the amino acid sequence represented by SEQ ID NO: 1 is serine. (3) The amino acid residue corresponding to the 330th amino acid residue of the amino acid sequence represented by SEQ ID NO: 1 is alanine. (4) The amino acid residue corresponding to the 333rd amino acid residue of the amino acid sequence represented by SEQ ID NO: 1 is alanine. (5) The amino acid residue corresponding to the 354th amino acid residue of the amino acid sequence represented by SEQ ID NO: 1 is alanine.

The present invention makes it possible to improve the production yield of 3-hydroxyhexanedioic acid, (E)-hex-2-enedioic acid, and / or hexanedioic acid while reducing the by-production of acetic acid by enhancing the function of isocitrate lyase in a microorganism capable of producing 3-hydroxyhexanedioic acid, (E)-hex-2-enedioic acid, and / or hexanedioic acid. The present invention further makes it possible to improve the production yield of 3-hydroxyhexanedioic acid by increasing the expression level of YnfM or a homolog thereof in a microorganism capable of producing 3-hydroxyhexanedioic acid.

The present invention relates to the efficient delivery of anti-infective activity, immune modulators, or growth-promoting biomolecules directly to the gastrointestinal tract of animals via a biodelivery platform.SOLUTION: The biodelivery platform can be a genetically modified microorganism. Delivery can be achieved using Lactobacillus species fix in the gastrointestinal tract. The anti-infective activity can be a bactericidal or bacteriostatic peptide, an antibody or fragment thereof that specifically recognizes a pathogen, or a phage or lytic peptide derived from a phage that specifically targets a particular pathogen.SELECTED DRAWING: None

The present invention relates to efficient delivery of anti-infective activity, immunomodulatory factors, or growth-promoting biomolecules directly to the digestive tract of an animal via a live delivery platform. The live delivery platform can be a genetically modified microorganism. Delivery can be accomplished with a Lactobacillus sp which colonizes the gastrointestinal tract. The anti-infective activity can be a bacteriocidal or bacteriostatic peptide, an antibody or fragment thereof which specifically recognizes a pathogen, or a phage, or a lytic peptide from a phage which specifically targets a certain pathogen.